Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report

Article Oncology

Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study

Wenxian Wang et al.

Summary: The study found that TP53 and RB1 mutations were common in patients with SCLC transformation in China, regardless of whether first/second-generation or third-generation EGFR-TKIs were used. After transformation to SCLC, platinum-etoposide was the most common treatment regimen, and anlotinib showed good efficacy in these patients.

LUNG CANCER (2021)

添加到收藏夹

Review Oncology

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

Alessandro Leonetti et al.

Summary: Small cell lung cancer (SCLC) transformation is a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma, impacting patients' prognosis. Combining platinum-etoposide chemotherapy after SCLC transformation could be an effective treatment strategy. Further clinical studies are needed to explore the efficacy of this combination in treating SCLC transformation as resistance mechanism to osimertinib.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology